Thursday, 19 Sep 2019

You are here

Adjuvant Herpes Zoster Subunit Vaccine is 97% Effective in Adults

The hazards of live virus vaccines are familiar to those who manage immunosuppression in the setting of inflammatory or autoimmune disease.  One in three adults will contract "shingles" (VZV) infection in their lifetime.  Given the pain and mobidity associated with this infection, the development of this VZV glycoprotein with adjuvant represents a significant advance.  15,411 normal adults over age 50 yrs were included in this phase III study and shown to have 97% protection against VZV infection. Injection site reactions/pain and myalgia were more frequent in the vaccine treated patients, but serious adverse were similar between groups.
Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Checkpoint Inhibitors: Who Gets Myocarditis?

The usual risk factors for myocarditis may not apply to who gets it while on immune checkpoint inhibiting cancer drugs, an FDA adverse event database suggested.

NSAIDs Mediate Cardiovascular Risk in OA

NSAIDs have been linked to an increased risk of cardiovascular disease, but does this also hold for osteoarthritis (OA) patients.

Tofacitinib Gets a New Boxed Warning for Blood Clots and Death with Higher Doses

The U.S. Food and Drug Administration has approved new warnings about an increased risk of blood clots and of death with the 10 mg twice daily dose of tofacitinib (Xeljanz, Xeljanz XR), which is used in patients with ulcerative colitis. 

EHR-Related Adverse Events Usually Involve Medications

Concerns about the unintended risks inherent in electronic health records (EHR) by analysis of EHR–related harms identified from large database of malpractice suits and claims; they found that EHR related adverse events exist, and may be associated with an severe harms and uncommonly, death.

Methotrexate Use Not Linked to Interstitial Lung Disease in RA

People with rheumatoid arthritis have a significant risk of developing interstitial lung disease (RA-ILD), yet there is often a question as to whether methotrexate (MTX) exposure can cause or worsen ILD.  A controlled cohort study suggests that MTX use is not associated with an increased risk of RA-ILD and instead, there is evidence suggesting MTX use may delay the onset of ILD.